Brevan Howard Capital Management LP Invests $6.25 Million in Teva Pharmaceutical Industries Ltd. $TEVA

Brevan Howard Capital Management LP purchased a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, Holdings Channel.com reports. The fund purchased 309,300 shares of the company’s stock, valued at approximately $6,248,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Howard Bailey Securities LLC boosted its stake in Teva Pharmaceutical Industries by 3.5% during the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock valued at $292,000 after buying an additional 494 shares during the period. ASR Vermogensbeheer N.V. increased its holdings in Teva Pharmaceutical Industries by 1.6% during the 3rd quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after purchasing an additional 515 shares during the period. Retirement Planning Co of New England Inc. raised its holdings in Teva Pharmaceutical Industries by 1.8% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock worth $671,000 after purchasing an additional 588 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of Teva Pharmaceutical Industries by 0.5% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock valued at $1,981,000 after purchasing an additional 615 shares during the period. Finally, Smartleaf Asset Management LLC grew its holdings in Teva Pharmaceutical Industries by 6.1% in the third quarter. Smartleaf Asset Management LLC now owns 10,794 shares of the company’s stock worth $207,000 after purchasing an additional 624 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of research analyst reports. Truist Financial upped their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Stock Down 2.6%

Shares of NYSE:TEVA opened at $28.54 on Monday. The business has a fifty day moving average of $32.91 and a two-hundred day moving average of $26.74. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market cap of $32.81 billion, a P/E ratio of 23.78, a PEG ratio of 9.56 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the transaction, the insider directly owned 10,914 shares in the company, valued at $345,646.38. This trade represents a 9.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard Daniell sold 17,295 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president directly owned 85,755 shares of the company’s stock, valued at $2,715,860.85. This represents a 16.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 948,499 shares of company stock worth $30,897,071. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.